Press release - 17/11/2026 When Brake Cells Become Killer Cells: Double Honor for DKFZ Researcher Julius Michel Julius Michel, a postdoctoral researcher at the German Cancer Research Center, has received two awards: the Craig Tendler Award for Myeloma Research from the American Society of Hematology - awarded for the first time and accompanied by a $10,000 prize - as well as another award from the society.https://www.gesundheitsindustrie-bw.de/en/article/press-release/when-brake-cells-become-killer-cells-double-honor-dkfz-researcher-julius-michel
Press release - 16/11/2026 AI and life sciences: two new research training groups at Universität Heidelberg Heidelberg University has been successful in the current approval round of the German Research Foundation with two applications for the funding of Research Training Groups. RTG 3251 “From Omics to Mechanisms”, which is located in the life sciences, seeks to develop new methods of obtaining, analyzing and interpreting extensive biological datasets. Research Training Group 3270 “Generative AI in the Sciences” focuses on artificial intelligence.https://www.gesundheitsindustrie-bw.de/en/article/press-release/ai-and-life-sciences-two-new-research-training-groups-universitaet-heidelberg
Press release - 12/11/2026 DKFZ Sets Records for ERC Synergy Grants A historic success for the German Cancer Research Center (DKFZ): Four DKFZ researchers are receiving one of the prestigious ERC Synergy Grants this year—more than ever before at a single institution in a single funding round. Three of the four international research consortia are coordinated by the DKFZ. In total, the projects will receive approximately 44.5 million euros, of which about 13.7 million euros will go to the DKFZ.https://www.gesundheitsindustrie-bw.de/en/article/press-release/dkfz-sets-records-erc-synergy-grants
Press release - 02/11/2026 Stem Cells in Deep Sleep as a Secret Reserve Researchers at the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute have discovered a group of particularly long-lived blood stem cells in mice. These cells remain in a dormant state for an exceptionally long time while retaining their ability to generate new blood cells. This newly discovered cell population may be responsible for sustaining blood regeneration and immune defense throughout a mouse’s entire life.https://www.gesundheitsindustrie-bw.de/en/article/press-release/stem-cells-deep-sleep-secret-reserve
Press release - 19/10/2026 New Biotech Master’s Degree Launches at Ulm University: Pharmaceutical and Molecular Biotechnology How do RNA-, protein- or stem cell-based therapies work? How can data science methods from bioinformatics and artificial intelligence be used to develop new pharmaceutical active substances? Students at Ulm University are learning this in the new master’s programme in Pharmaceutical and Molecular Biotechnology (PMB).https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-biotech-masters-degree-launches-ulm-university-pharmaceutical-and-molecular-biotechnology
Press release - 16/10/2026 A new approach to osteoporosis treatment Disabling a bone formation inhibiting protein molecule How can the human body be stimulated to build more bone, thus helping those affected by osteoporosis? Researchers in Ulm have investigated the role played by the protein molecule Axl in this process. Their efforts were successful: in a study, they demonstrated that Axl inhibits bone formation – and that cells produce significantly more bone tissue when the molecule is blocked using medication. There are no discernible harmful side effects. https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-osteoporosis-treatment-disabling-bone-formation-inhibiting-protein-molecule
Press release - 05/10/2026 A Matter of Quantity: A Universal Target for CAR-T Cells Against Cancer CAR-T cell therapies have proven successful in treating several types of blood and lymphoid cancers. However, their use in treating other tumors is significantly more challenging, in part because suitable target structures are lacking.https://www.gesundheitsindustrie-bw.de/en/article/press-release/matter-quantity-universal-target-car-t-cells-against-cancer-1
Press release - 05/10/2026 A Matter of Quantity: A Universal Target for CAR-T Cells Against Cancer CAR-T cell therapies have proven successful in treating several types of blood and lymphoid cancers. However, their use in treating other tumors is significantly more challenging, in part because suitable target structures are lacking.https://www.gesundheitsindustrie-bw.de/en/article/press-release/matter-quantity-universal-target-car-t-cells-against-cancer
Press release - 05/10/2026 How blood flow controls liver function The liver is organized into distinct zones in which liver cells perform different functions. The blood vessels of the liver play an important role in this spatial organization: the endothelial cells lining the vessels provide signals that instruct neighboring liver cells and help determine their function. But how do endothelial cells know which signals to produce?https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-blood-flow-controls-liver-function
Press release - 30/09/2026 How cells pass on regulatory information A project funded by the Baden-Württemberg Stiftung at the Max Planck Institute of Immunobiology and Epigenetics in Freiburg is investigating the interplay between RNA modifications and epigenetic mechanisms during cell division – and its potential significance for treatment resistance in cancer.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-cells-pass-regulatory-information
Press release - 24/09/2026 Enzyme Beads for More Sustainable Chemistry Thanks to enzyme-based biocatalysis, an enormous range of pharmaceutical active ingredients and other complex molecules can be synthesized in an environmentally friendly manner. Researchers at the Karlsruhe Institute of Technology (KIT) have now developed a technology that allows to assemble enzymes into millimeter-sized, storable beads. In this process, the enzymes not only act as catalysts but also constitute the beads’ material itself.https://www.gesundheitsindustrie-bw.de/en/article/press-release/enzyme-beads-more-sustainable-chemistry
Press release - 09/09/2026 International Research on Bioengineering of the Mitochondrial Genome While the cell nucleus contains almost all of the genome, the mitochondria – the powerhouses of the cell – have their own small genetic code. It consists of only 37 genes, which are organized in circular DNA – mtDNA, for short. Defects in the mitochondrial genome are related to incurable neurodegenerative and metabolic diseases, cancer and also aging processes.https://www.gesundheitsindustrie-bw.de/en/article/press-release/international-research-bioengineering-mitochondrial-genome
Panosome GmbH – a parasite as the basis for innovative immunotherapies - 26/08/2026 Reaching the unreachable: new approaches to challenging drug targets Modern medicines act with remarkable precision. Antibodies, for example, recognise their molecular targets much like a key fits into its corresponding lock. However, certain targets like small molecules or carbohydrates remain difficult to target. The start-up Panosome aims to eliminate these blind spots with a novel immunotherapy platform that harnesses sophisticated masters of immune evasion: trypanosomes.https://www.gesundheitsindustrie-bw.de/en/article/news/reaching-unreachable-new-approaches-challenging-drug-targets
Press release - 13/08/2026 PRAME-specific T-cell therapy in an adolescent with metastatic kidney tumor Researchers and physicians at the Hopp Children's Cancer Center Heidelberg (KiTZ) and other leading cancer centers report an exceptional treatment success in an adolescent with an advanced, therapy-resistant kidney tumor. Using a novel, personalized T-cell therapy, they succeeded in completely pushing back the tumor disease despite multiple metastases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/prame-specific-t-cell-therapy-adolescent-metastatic-kidney-tumor
Press release - 12/08/2026 Industrial-scale biotech production of proteins and vitamins economically viable Researchers are developing biotechnological processes that enable microbes to produce proteins and vitamins for human consumption using basic chemical ingredients, such as carbon dioxide, hydrogen and oxygen – entirely bypassing livestock farming and agriculture. Because these methods also require energy input, they are popularly called “power-to-protein” and “power-to-vitamin” processes.https://www.gesundheitsindustrie-bw.de/en/article/press-release/industrial-scale-biotech-production-proteins-and-vitamins-economically-viable
Press release - 11/08/2026 Programming membrane transport New in Nature Nanotechnology: A DNA origami nanosyringe introduces mechanically controlled molecular transport into synthetic cells. This opens new opportunities for synthetic biology, engineered biointerfaces and molecular therapeutics.https://www.gesundheitsindustrie-bw.de/en/article/press-release/programming-membrane-transport
Press release - 10/08/2026 Immune Cells in Bone Marrow Cancer: Limited Defense Readiness A team led by researchers from the German Cancer Research Center, the HI-STEM* Stem Cell Institute, and Medical Clinic V at Heidelberg University Hospital has characterized T cells in the bone marrow in cases of multiple myeloma and acute myeloid leukemia: A specific group of tumor-reactive T cells can recognize and fight cancer cells, but is often not sufficiently activated. Nevertheless, the number of these cells influences the prognosis.https://www.gesundheitsindustrie-bw.de/en/article/press-release/immune-cells-bone-marrow-cancer-limited-defense-readiness
Press release - 07/08/2026 Can Protein Building Blocks Protect Against Vascular and Kidney Damage? Researchers from the Medical Faculty Heidelberg, the Medical Faculty Mannheim, and the Centre for Organismal Studies at Heidelberg University have launched a new research project investigating so-called dipeptides. The consortium aims to determine which dipeptides have the strongest protective effects and how they could be harnessed in future therapies for vascular and kidney diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/can-protein-building-blocks-protect-against-vascular-and-kidney-damage
Press release - 31/07/2026 A new genetic tool helps researchers uncover the logic of gene regulation Researchers use synthetic biology approaches to test hundreds of DNA sequences for their effect on regulating gene expression. The human genome contains over 20,000 genes. However, at any given time and in a given cell, only a fraction of them are active. Researchers from EMBL Heidelberg’s Krebs Group have come up with an innovative experimental approach to understand how cells determine which genes to turn on and when.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-genetic-tool-helps-researchers-uncover-logic-gene-regulation
Press release - 31/07/2026 New insights into Malaria research: How molecular tethers and Asynchronous replication drive parasite proliferation Researchers from Heidelberg University’s Faculty of Medicine, Harvard Medical School, and the German Cancer Research Center (DKFZ) have uncovered key mechanisms underlying the proliferation of the malaria parasite Plasmodium. The molecular processes that govern the formation of infectious daughter parasites and new nuclei are essential for parasite survival and may therefore represent targets for future antimalarial therapies.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-insights-malaria-research-how-molecular-tethers-and-asynchronous-replication-drive-parasite-proliferation
Press release - 29/07/2026 ERC Synergy Grant has started The international research project MitoContact is dedicated to investigating how organelles within a cell communicate and interact with other cellular components. Kai Johnsson, Director at the Max Planck Institute for Medical Research, has received funding from the ERC for this project. The findings are expected to provide new insights into fundamental cellular processes and contribute to a better understanding of various diseases. https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-synergy-grant-has-started
Press release - 23/07/2026 Flabby and flexible: How Machine Learning helps to build new proteins A team of researchers from the Heidelberg Institute for Theoretical Studies and the Max Planck Institute for Polymer Research have developed a model that learns how to generate proteins whose structures are highly flexible, even with patterns that are uncommon in natural proteins. Their work, marks a step towards the goal of designing new proteins for applications in biotechnology, therapeutics and environmental research.https://www.gesundheitsindustrie-bw.de/en/article/press-release/flabby-and-flexible-how-machine-learning-helps-build-new-proteins
Press release - 17/07/2026 NovoTags: AI-designed proteins help scientists see inside living cells Researchers have designed synthetic and inducible proteins that bind to bright fluorescent dyes with high specificity and affinity, significantly expanding the toolkit for multicolour imaging of proteins inside cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/novotags-ai-designed-proteins-help-scientists-see-inside-living-cells
Press release - 09/07/2026 DKFZ Innovation Award and DKFZ Patient Expert Award Presented The Friends of the German Cancer Research Center (DKFZ) support the DKFZ and aim to help strengthen its position in the international arena. With the DKFZ Innovation Award, presented at this year’s annual reception, the association honors Helmut Salih, a researcher whose innovative work bridges the gap between immunological research and patient care.https://www.gesundheitsindustrie-bw.de/en/article/press-release/dkfz-innovation-award-and-dkfz-patient-expert-award-presented
Press release - 03/07/2026 Vaccine Against Brain Tumors Shows Promising Long-Term Results A novel vaccination strategy against certain malignant brain tumors could fundamentally improve treatment for patients. Researchers from the German Cancer Research Center, Mannheim University Medical Center, Heidelberg University Hospital, and numerous partner institutions* have published encouraging long-term results from a clinical trial involving a vaccine that activates the immune system against a common genetic mutation in these tumors.https://www.gesundheitsindustrie-bw.de/en/article/press-release/vaccine-against-brain-tumors-shows-promising-long-term-results